RenovoRx Inc(RNXT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.31 | Insider Own | 3.49% | Shs Outstand | 45.1M | Perf Week | -29.76% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | 46.67% | Insider Trans | 1.61% | Shs Float | 43.5M | Perf Month | 53.91% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.06 | Inst Own | 20.38% | Short Float | 1.55% | Perf Quarter | 108.06% |
| Income | -0.01B | P/S | 40.34 | EPS this Y | 17.97% | Inst Trans | -0.17% | Short Ratio | 1.07 | Perf Half Y | 122.61% |
| Sales | 0.00B | P/B | 8.89 | EPS next 5Y | - | ROA | -97.83% | Short Interest | 0.67M | Perf YTD | 110.69% |
| Book/sh | 0.2 | P/C | 8.43 | EPS past 3/5Y | 33.86% 6.34% | ROE | -125.23% | 52W High | -31.66% ($2.59) | Perf Year | 51.28% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | - | ROIC | -132.98% | 52W Low | 152.64% ($0.70) | Perf 3Y | 18% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.29% | Gross Margin | 84.41% | Volatility(W/M) | 17.51% 14.79% | Perf 5Y | -81.09% |
| Dividend TTM | - | EV/Sales | 35.75 | Sales Y/Y TTM | 198.49% | Oper. Margin | -685.22% | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.53 | EPS Q/Q | 22.22% | Profit Margin | -621.71% | RSI (14) | 53.97 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.74 | Sales Q/Q | 115.4% | SMA20 | 5.42% ($1.68) | Beta | 0.94 | Target Price | $7.12 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/12 | SMA50 | 41.99% ($1.25) | Rel Volume | 2.59 | Prev Close | $2 |
| Employees | 17 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 17.24% 29.16% | SMA200 | 75.37% ($1.01) | Avg Volume(3M) | 0.63M | Price | $1.77 |
| IPO | 2021/8/26 | Option/Short | No/Yes | Trades | 4148 | Volume | 1,630,940 | Change | -11.28% |
Company
RNXT is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A clinical-stage biotech developing the RenovoCath technology, which delivers chemotherapy directly into the tumor-feeding artery for the treatment of pancreatic cancer. In a Phase 3 trial, the technology demonstrated an 8-month delay in cancer progression, and it has also received FDA Orphan Drug Designation. Final data is expected in 2027.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
RNXT has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +18.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +18.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 20.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $80M.
RNXT $80M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is RNXT?
RNXT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RNXT?
The market cap of RNXT is approximately $80M, ranking 4,697 within its sector.
What is the 52-week high and low for RNXT?
RNXT has recorded a 52-week high of $2.59 and a low of $0.70.
